1. Technological Innovation for Health Abdallah S Daar McLaughlin-Rotman Centre for Global Health UHN/University of Toronto

2. Necessary ingredients Failures Success stories Empirical studies Innovative solutions

3. Necessary Ingredients 1.Operational access to good science 2.Identification and prioritizing needs 3.Confidence in developing ideas 4.Supportive environment (policies, entrepreneurship, ideology, culture, private sector) 5.Tech transfer and IP systems 6.Total skill sets available for tech development, commercialization and marketing 7.Provision of capital: proof of principle, valley of death, venture capital 8.Supportive health systems capable of internalizing tech

4. Failure : Hep B Vaccine Presentation Title / Date Ulmer, J.B. and Liu, M.A. 2002. Ethical Issues for vaccines and immunization. Nat Rev Immunol 2 291-296 discovered- 1967 1 st vaccine- 1969 available- in U.S. 1982

5. Success: Cuba and Meningitis B Vaccine Presentation Title / Date

6. Success and Failure: A to Z Presentation Title / Date

7. Stagnant Technologies 1.Natural Products Extraction of Artemisia Annua: Tanzania Tanzed: an anti-HIV protein based compound in Tanzania 2.Diagnostics Dip-stick Schistosomiasis: Ghana Rapid HIV Diagnostic Kits: Kenya 3.Mosquito Repellants: Nigeria, Kenya 4.Pyrethrum-based Mosquito Nets: Rwanda

8. Presentation Title / Date Empirical Studies: Ghana, Tanzania and Rwanda Key findings based on a 110 interviews 1.Lack of synergy and knowledge flows between various stakeholders 2.Inadequate financial incentives/resources for commercialization 3.Unexploited potential to commercialize innovative products

9. Presentation Title / Date Innovative Solutions 1.Held stakeholder workshops in Ghana, Tanzania and Rwanda with over 200 participants Our preliminary findings were validated and the concept of Convergence Innovation resonated with all stakeholders 2.Developed business plans and presented them to Science Ministers Ministers appointed local steering committees to implement Convergence Platforms

10. Presentation Title / Date What is Convergence Innovation?

11. Presentation Title / Date African Life Sciecnes Convergence Model Centre`s of innovation where we bring together all the elements needed for success: science, business, capital.

12. Presentation Title / Date How might a convergence centre be funded? In particular the Bank should support the development of national and regional centers of excellence in the health sciences and in Energy and environmental technologies. There are significant potential benefits from strengthening the linkages between life sciences and the private sector. These centers would facilitate and incubate innovation, supporting entrepreneurship and developing technologies.

13. Presentation Title / Date 1.We identified very little venture capital invested into life sciences 2.IFC has announced a health venture fund for Africa 3.Plans to mobilize up to $1B, including an $350M equity vehicle with initial investments of $100M 4.Partnerships will be important to mitigate and tier risk and demonstrate that this market failure can be bridged How Might Technologies Be Funded?

14. Lab to Village Presentation Title / Date

15. Thank You Presentation Title / Date Additional funding partners for the McLaughlin-Rotman Centre for Global Health can be found at www.mrcglobal.org